Henry Schein Inc HSIC
We take great care to ensure that the data presented and summarized in this overview for HENRY SCHEIN INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HSIC
View all-
Vanguard Group Inc Valley Forge, PA14.7MShares$957 Million0.02% of portfolio
-
Black Rock Inc. New York, NY9.54MShares$620 Million0.01% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI6.53MShares$424 Million0.72% of portfolio
-
State Street Corp Boston, MA5.98MShares$388 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY5.91MShares$384 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA4.96MShares$322 Million0.07% of portfolio
-
American Century Companies Inc Kansas City, MO4.8MShares$312 Million0.2% of portfolio
-
Pendal Group LTD4.18MShares$272 Million2.74% of portfolio
-
Geode Capital Management, LLC Boston, MA3.17MShares$206 Million0.02% of portfolio
-
Generation Investment Management LLP London, X02.74MShares$178 Million1.02% of portfolio
Latest Institutional Activity in HSIC
Top Purchases
Top Sells
About HSIC
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Insider Transactions at HSIC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
Mar 19
2025
|
Philip A Laskawy |
SELL
Open market or private sale
|
Direct |
2,604
-9.5%
|
$184,884
$71.04 P/Share
|
Mar 19
2025
|
Michael S Ettinger EVP & Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
105
-0.1%
|
-
|
Mar 19
2025
|
Bradford C Connett CEO, NA Distribution Group |
SELL
Open market or private sale
|
Direct |
4,036
-6.05%
|
$286,556
$71.15 P/Share
|
Mar 18
2025
|
Michael S Ettinger EVP & Chief Operating Officer |
SELL
Bona fide gift
|
Direct |
350
-0.34%
|
-
|
Mar 14
2025
|
Walter Siegel Sr. VP & Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,998
-8.47%
|
-
|
Mar 14
2025
|
Ronald N. South SVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,954
-7.87%
|
-
|
Mar 14
2025
|
Thomas C Popeck CEO, Henry Schein Products |
SELL
Sale (or disposition) back to the issuer
|
Direct |
535
-1.45%
|
-
|
Mar 14
2025
|
Michael S Ettinger EVP & Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,390
-4.92%
|
-
|
Mar 14
2025
|
Mark E Mlotek EVP, Chief Strategic Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,433
-6.22%
|
-
|
Mar 14
2025
|
Bradford C Connett CEO, NA Distribution Group |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,477
-4.95%
|
-
|
Mar 14
2025
|
Stanley M Bergman Chairman, CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,617
-7.82%
|
-
|
Mar 14
2025
|
James P Breslawski President |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,315
-3.06%
|
-
|
Mar 14
2025
|
Andrea Albertini CEO, Global Dist. & Tech. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,087
-2.98%
|
-
|
Mar 12
2025
|
Mark E Mlotek EVP, Chief Strategic Officer |
SELL
Bona fide gift
|
Direct |
340
-0.33%
|
-
|
Mar 12
2025
|
Stanley M Bergman Chairman, CEO |
SELL
Bona fide gift
|
Direct |
950
-0.27%
|
-
|
Mar 10
2025
|
Michael S Ettinger EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,507
+19.48%
|
-
|
Mar 10
2025
|
Mark E Mlotek EVP, Chief Strategic Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,507
+20.35%
|
-
|
Mar 10
2025
|
Stanley M Bergman Chairman, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
102,913
+22.51%
|
-
|
Mar 10
2025
|
James P Breslawski President |
BUY
Grant, award, or other acquisition
|
Direct |
3,313
+1.58%
|
-
|
Mar 10
2025
|
Ronald N. South SVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,880
+18.37%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 258K shares |
---|
Payment of exercise price or tax liability | 49.5K shares |
---|---|
Open market or private sale | 49.8K shares |
Sale (or disposition) back to the issuer | 62.8K shares |
Bona fide gift | 12K shares |
Other acquisition or disposition | 2.13K shares |